Top Markets
Coin of the day
Vaxxinity, Inc. Vaxxinity, Inc.

Vaxxinity, Inc.

VAXX
주식 순위 #41693
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in... Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
주가
$0.0001
마지막 동기화: 2026-08-11
시가총액
$12.68K
변동 (1일)
0.00%
변동 (1년)
-99.76%
국가
US
거래 Vaxxinity, Inc. (VAXX)

카테고리

Vaxxinity, Inc. (VAXX)의 주식 분할 이력
Vaxxinity, Inc. 주식 (심볼: VAXX)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 13, 2026에 발생했습니다.
Aug 13, 2026 이전에 매수한 VAXX 주식 1주는 현재 0주의 VAXX 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE